Onset age is associated with outcome of radioiodine therapy in Graves' disease

Endocrine Journal

Volumn 51, Issue 2, 2004, Pages 127-132

  Yamashita, Yasuyo ^a   Yamane, Kiminori ^a   Tamura, Tomoko ^a   Okubo, Masamichi ^a   Kohno, Nobuoki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Graves' disease; Hyperthyroidism; Radioiodine dose; Radioiodine therapy; Thyroid

Indexed keywords

RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; DATA ANALYSIS; DISEASE ASSOCIATION; DOSE CALCULATION; DRUG EFFECT; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; HYPOTHYROIDISM; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; RADIATION DOSE; THYROID FUNCTION; THYROID HORMONE BLOOD LEVEL;

ADULT; AGE OF ONSET; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FOLLOW-UP STUDIES; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; LOGISTIC MODELS; MALE; MIDDLE AGED; PROGNOSIS; THYROID GLAND; TIME FACTORS; TREATMENT OUTCOME;

EID: 2442691356     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.51.127     Document Type: Article

References (24)

1. Hamilton JG, Lawrence JH (1942) Recent clinical developments in the therapeutic application of radio-phosphorus and radio-iodine. J Clin Invest 21: 624.
2. Hertz S, Roberts A (1942) Application of radioactive iodine in the therapy of Graves' disease. J Clin Invest 21: 624.
3. Allhabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC L, Franklyn JA (2000) Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 85: 1038-1042.
4. Allhabadia A, Daykin J, Sheppard MC, Gough SCL, Franklyn JA (2001) Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab 86: 3611-3617.
5. 131I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 87: 1073-1077.
6. 131I treatment methods for Graves' disease. Endocrinol Jpn 70: 995-1006 (in Japanese).
7. Nodyke RA, Gilbert FI (1991) Optimal iodine-131 I in Graves' hyperthyroidism in Graves' disease. J Nucl Med 32: 411-416.
8. 131I therapy for Graves' disease. Clin Endocrinol (Oxf) 28: 487-496.
9. Haase A, Bahre M, Lauer I, Meller B, Riter E (2000) Radioiodine therapy in Graves' hyperthyroidism: Determination of individual optimum target dose. Exp Clin Endocrinol Diabetes 108: 133-137.
10. Reinhardt MJ, Brink I, Joe AY, Von Mallek D, Ezziddin S, Palmedo H, Krause TM (2002) Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging 29: 1118-1124.
11. Kaise K, Kaise N, Yoshida K, Fukazawa H, Mori K, Yamamoto M, Sakurada T, Saito S, Yoshinaga K (1991) Thyrotropin receptor antibody activities significantly correlate with the outcome of radioiodine (131I) therapy for hyperthyroid Graves' disease. Endocrinol Jpn 38: 429-433.
12. Murakami Y, Takamatsu J, Sakane S, Kuma K, Ohsawa N (1996) Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. J Clin Endocrinol Metab 81: 3257-3260.
13. Nagayama Y, Izumi M, Nagataki S (1989) The management of hyperthyroism due to Graves' disease in Japan in 1988 The Japan Thyroid Association. Endocrinol Jpn 36: 299-314.
14. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M (1991) Difference and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1: 129-135.
15. Allen HC, Goodwin WE (1942) The scintillation counter as an instrument for in vivo determination of thyroid weight. Radiology 58: 68-79.
16. Goodwin WE (1953) Thyroid gland weight determination from thyroid scintigram with postmortem verification. Radiology 61: 88.
17. Berg G, Michanek A, Holmberg E, Nystrom E (1996) Clinical outcome of radioiodine treatment of hyperthyroidism: a follow-up study. J Intern Med 239: 165-171.
18. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV (1974) Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 38: 976-998.
19. Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, Latrofa F, Mammoli C, Lippi F, Ceccarelli C, Pinchera A (1998) Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking anti-bodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 83: 40-46.
20. Yamada T, Aizawa T, Koizumi Y, Komiyama I, Ichikawa K, Hashimoto K (1994) Age-related therapeutic response to antithyroid drug in patients with hyperthyroid Graves' disease. J Am Geriatric Soc 42: 513-516.
21. Vitti P, Rago T, Chiovato L, Pallinis S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A (1997) Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 7: 369-375.
22. Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes, Buell U (1999) Success rate of radioiodine treatment in patients with Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 84: 1229-1233.
23. Korosci TM (1995) Thionamides alter the efficacy of radioiodine treatment in patients with Graves' disease. South Med J 88: 831-836.
24. Tuttle R, Patience T, Budd S (1995) Treatment with propylthiouracil before radioactive iodine therapy is associated with higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease. Thyroid 5: 243-247.